Ignite Creation Date:
2025-12-24 @ 1:37 PM
Ignite Modification Date:
2026-01-29 @ 6:16 PM
Study NCT ID:
NCT05764395
Status:
SUSPENDED
Last Update Posted:
2024-10-10
First Post:
2023-02-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization: